Logo for Liminal BioSciences Inc

Liminal BioSciences Investor Relations Material

Latest events

Logo for Liminal BioSciences Inc

Q4 2022

Liminal BioSciences
Logo for Liminal BioSciences

Q2 2023

8 Aug, 2023
Logo for Liminal BioSciences

Q1 2023

9 May, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies

Latest reports from Liminal BioSciences Inc

Access all reports
Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis with fezagepras or related derivatives and respiratory diseases. It is also developing antagonist candidate programs, including G-protein coupled receptor 84 and Oxo-eicosanoid receptor 1, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019